White Blood Cell Population May Serve as MS Biomarker
|
By LabMedica International staff writers Posted on 29 Jul 2019 |

Image: A CyTOF mass cytometer (Photo courtesy of Wikimedia Commons).
A discrete population of white blood cells was found to be present in samples taken from patients with multiple sclerosis (MS) and this group of cells may serve both diagnostic and therapeutic roles.
MS is among the class of chronic inflammatory diseases that is modulated by cytokine dysregulation. To better understand the link between cytokines and MS, investigators at the University of Zurich (Switzerland) sought to determine the characteristic cellular and cytokine polarization profile in patients with relapsing–remitting multiple sclerosis (RRMS) by using advanced high-dimensional single-cell mass cytometry (CyTOF).
CyTOF is a mass spectrometry technique based on inductively coupled plasma mass spectrometry and time of flight mass spectrometry used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent in the form of a mist through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores, which have broad emission spectra.
The use of CyTOF technology allowed the investigators to identify an expanded T helper cell subset in patients with MS, characterized by the expression of granulocyte–macrophage colony-stimulating factor and the C-X-C chemokine receptor type 4. This cellular signature, which included expression of very late antigen 4 in peripheral blood, was also enriched in the central nervous system of patients with relapsing–remitting multiple sclerosis. In independent validation cohorts, the investigators confirmed that this cell population was increased in patients with MS compared with other inflammatory and non-inflammatory conditions.
"We identified a specific population of white blood cells augmented in the peripheral blood of MS patients that have two properties characteristic of MS: They can move from the blood to the central nervous system and there they can cause inflammation of the nerve cells," said senior author Dr. Burkhard Becher, professor of experimental immunology at the University of Zurich. "Our data clearly indicate a stringent association of this signature to MS, and we believe that the identification of such an easily accessible biomarker brings important value for MS monitoring."
The report was published in the July 22, 2019, online edition of the journal Nature Medicine.
Related Links:
University of Zurich
MS is among the class of chronic inflammatory diseases that is modulated by cytokine dysregulation. To better understand the link between cytokines and MS, investigators at the University of Zurich (Switzerland) sought to determine the characteristic cellular and cytokine polarization profile in patients with relapsing–remitting multiple sclerosis (RRMS) by using advanced high-dimensional single-cell mass cytometry (CyTOF).
CyTOF is a mass spectrometry technique based on inductively coupled plasma mass spectrometry and time of flight mass spectrometry used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent in the form of a mist through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores, which have broad emission spectra.
The use of CyTOF technology allowed the investigators to identify an expanded T helper cell subset in patients with MS, characterized by the expression of granulocyte–macrophage colony-stimulating factor and the C-X-C chemokine receptor type 4. This cellular signature, which included expression of very late antigen 4 in peripheral blood, was also enriched in the central nervous system of patients with relapsing–remitting multiple sclerosis. In independent validation cohorts, the investigators confirmed that this cell population was increased in patients with MS compared with other inflammatory and non-inflammatory conditions.
"We identified a specific population of white blood cells augmented in the peripheral blood of MS patients that have two properties characteristic of MS: They can move from the blood to the central nervous system and there they can cause inflammation of the nerve cells," said senior author Dr. Burkhard Becher, professor of experimental immunology at the University of Zurich. "Our data clearly indicate a stringent association of this signature to MS, and we believe that the identification of such an easily accessible biomarker brings important value for MS monitoring."
The report was published in the July 22, 2019, online edition of the journal Nature Medicine.
Related Links:
University of Zurich
Latest Molecular Diagnostics News
- Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
- New Molecular Marker Helps Predict Multiple Myeloma Prognosis
- Gene Expression Test Supports Metastatic Risk Assessment in Melanoma
- Multiplex PCR Test Identifies Seven STI Pathogens in One Hour
- CSF Sequencing Test Aligns with Updated Brain Tumor Guidelines
- Framework Outlines Genomic Testing Strategy for Safer Drug Dosing in Africa
- Point-of-Care PCR Panel Delivers Vaginitis Results in 20 Minutes
- Blood Test Reveals Hidden Pancreatic Cancer After Treatment
- Gene Expression Test Refines Melanoma Biopsy Decision-Making
- Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
- Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
- Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
- Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
- Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
- Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
- RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more








